Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwMyeloma 2018 | How can novel targets be incorporated into MM treatment?

From the Myeloma 2018 meeting, held in San Diego, CA, the experts discuss novel targets in multiple myeloma (MM), including BRD4, Pykfvye and MCL1, and induced protein degradation, such as that via PROTAC. Faith Davies, MD, MRCP, MRCPath, of UAMS Myeloma Institute, Little Rock, AR, chairs the discussion with Leif Bergsagel, MD, of the Mayo Clinic, Phoenix, AZ, Robert Orlowski, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, and Keith Stewart, MB, ChB, of the Mayo Clinic. Dr Bergsagel discussed the already known targets in MM which still do not have a drugs specific for them. Dr Stewart comments on the emerging targets, including proteasome targets PYKfyve, MCL1 targets, venetoclax and immunotherapies. Finally, Dr Orlowski describes the novel technologies that target proteins to instigate their degradation.